Graceway Pharmaceuticals obtained commercialization rights to three dermatological molecules from Pfizer. The acquisition and license agreement includes related transferred or licensed intellectual properties.

This transaction is part of Pfizer’s plan to out-license noncore programs; the firm identified CNS diseases, oncology, and cardiovascular diseases as its focus. Pfizer continues to be responsible, however, for performing developmental and clinical services for these three molecules.

[ad]

Of the acquired therapeutic candidates, two target the treatment of oily skin and acne: early-stage stearoyl CoA desaturase 1 inhibitor and Phase II cholesterol-acyltransferase (ACAT) inhibitor. The latter reportedly offers a new mechanism of action to address these common conditions and is understood to work by reducing skin surface sebum production. In addition, Graceway will acquire an activin-like kinase 5 (ALK-5) inhibitor, currently in early preclinical development for the reduction of surgical and traumatic scar formation.

Source: GEN News

Popularity: 2% [?]

Pfizer and GlaxoSmithKline—the number one and two drug companies by pharmaceutical sales—are reshaping their R&D organizations, with job cuts likely.

Pfizer’s biannual drug pipeline update highlighted candidates in Phase III development, most of which are in its high-priority research areas of oncology, pain, inflammation, diabetes, schizophrenia, and Alzheimer’s disease.

Separately, Martin Mackay, president of Pfizer global R&D, told managers in an internal memo that Pfizer is ending research in anemia, bone health, obesity, gastrointestinal disease, and some cardiovascular diseases. “We are investing in the most promising disease areas, where there is strong unmet medical need, favorable markets, and an opportunity to advance medical science,” Mackay said. Read the full story

Popularity: 4% [?]